The recommended standard dosage of Tislelizumab for adults is 200 mg administered via intravenous infusion, once every 3 weeks.
The specific dosage shall be adjusted according to disease type, the patient’s physical condition, and treatment phase. The drug must be used strictly under medical supervision throughout the treatment; the regimen must not be modified without professional guidance.
1. Standard Dosage and Adjustment Principles
Standard adult dosage
200 mg via intravenous infusion once every 3 weeks; the infusion duration is recommended to be controlled at 30–60 minutes per administration.
Dosage adjustment
If severe adverse reactions occur (e.g., immune-related pneumonia, hepatitis), temporary suspension or permanent discontinuation may be required, as evaluated and determined by a physician.
No routine dosage adjustment is generally needed for special populations (e.g., patients with hepatic or renal impairment), but close monitoring is still required.
2. Administration Method and Precautions
Intravenous infusion standards
Inspect the drug for turbidity or precipitation before infusion.
Closely monitor for allergic reactions (e.g., fever, chills) during infusion.
Treatment cycle: Continue administration until disease progression, intolerable toxicity develops, or discontinuation is advised by a physician.
3. Key Clinical Considerations
Compliance with medical orders
Tislelizumab is a prescription drug. Patients must attend regular follow‑up visits; the physician will dynamically adjust the regimen based on efficacy and side effects.
Side effect management
Common side effects include fatigue, rash, thyroid dysfunction, etc. Severe side effects may involve immune‑mediated damage to normal tissues (e.g., enteritis, myocarditis).
Seek immediate medical attention if any discomfort occurs (e.g., persistent diarrhea, dyspnea).
4. Storage and Contraindications
Storage conditions
Unopened vials must be stored refrigerated at 2–8°C, protected from light; freezing is prohibited. The prepared solution must be used within 6 hours.
Contraindicated populations
Patients with hypersensitivity to any ingredient of the drug.
Patients with active autoimmune diseases.
Note: For any questions regarding medication use or abnormal symptoms during treatment, contact the attending physician promptly to avoid delayed management.
